After only two years of ownership, biotechnology company Cytogen announced last month that it sold its interest in its subsidiary Targon back to the original owner, pharmaceutical firm Elan of Dublin, Ireland. Elan purchased Targon for $2 million,
After only two years of ownership, biotechnology company Cytogen announced last month that it sold its interest in its subsidiary Targon back to the original owner, pharmaceutical firm Elan of Dublin, Ireland. Elan purchased Targon for $2 million, according to Cytogen. The subsidiary was formed in September 1996 to accelerate the two companies' development of cancer agents (SCAN 10/9/96), and to move Cytogen's work-in-progress agents Prostatec, Oncotec, and prostate-specific membrane antigen (PSMA) toward commercialization.
The Princeton, NJ, company also announced second-quarter results (end-June), posting revenue of $2.5 million, up slightly from $2.2 million for the same period in 1997. The company attributed its increased revenue to sales of ProstaScint, a prostate cancer imaging agent, and Quadramet, a bone pain palliative. ProstaScint earned $1.5 million in the second quarter, and Quadramet earned $253,000, the company reported. Net losses for the quarter were $4.7 million, as compared with $6.4 million in the previous year.
In other Cytogen news, the company named Joseph Reiser to the post of president and CEO, replacing interim chief executive John Bagalay.
Emerging AI Algorithm Shows Promise for Abbreviated Breast MRI in Multicenter Study
April 25th 2025An artificial intelligence algorithm for dynamic contrast-enhanced breast MRI offered a 93.9 percent AUC for breast cancer detection, and a 92.3 percent sensitivity in BI-RADS 3 cases, according to new research presented at the Society for Breast Imaging (SBI) conference.
The Reading Room Podcast: Current Perspectives on the Updated Appropriate Use Criteria for Brain PET
March 18th 2025In a new podcast, Satoshi Minoshima, M.D., Ph.D., and James Williams, Ph.D., share their insights on the recently updated appropriate use criteria for amyloid PET and tau PET in patients with mild cognitive impairment.
Can Abbreviated Breast MRI Have an Impact in Assessing Post-Neoadjuvant Chemotherapy Response?
April 24th 2025New research presented at the Society for Breast Imaging (SBI) conference suggests that abbreviated MRI is comparable to full MRI in assessing pathologic complete response to neoadjuvant chemotherapy for breast cancer.
Clarius Mobile Health Unveils Anterior Knee Feature for Handheld Ultrasound
April 23rd 2025The T-Mode Anterior Knee feature reportedly offers a combination of automated segmentation and real-time conversion of grayscale ultrasound images into color-coded visuals that bolster understanding for novice ultrasound users.